The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
where K is an optical constant and c is the solution concentration. Using a differential refractometer (DRI) to measure the concentration of the solution, an absolute molar mass can be calculated. More accurate measurements can be made by using a low-angle static light scattering (LALS) detector, which operates at a very low angle and therefore do not require angular effects to be corrected. However, these detectors are very sensitive to particles, which leads to noisy data and are therefore rarely used. LALS detectors have largely been replaced by MALS detectors, which measures scattered light at multiple angles simultaneously and extrapolates the data to θ = 0° to obtain a weight-average molar mass. The coupling of SEC with MALS detection have become the benchmark for the determination of absolute molecular mass, particularly averages masses and distributions. Viscometry detectors, although less common, also function as detectors of absolute molar mass. Unlike light scattering photometers which do not use a calibration curve, viscometers apply a universal calibration curve where the logarithm of intrinsic viscosity multiplied by molar mass can be plotted against the retention volume from SEC. This method is effective for calculating the absolute molar mass of a wide variety of polymers, including rod-like polymers and dendrimers. Several other methods of analysis are used to determine the absolute molar mass.
=== Types === The various saffron crocus cultivars give rise to thread types that are often regionally distributed and characteristically distinct. Varieties (not varieties in the botanical sense) from Spain, including the tradenames "Spanish Superior" and "Creme", are generally mellower in colour, flavour, and aroma; they are graded by government-imposed standards. Italian varieties are slightly more potent than Spanish. Greek saffron produced in the town of Krokos is PDO protected due to its particularly high-quality colour and strong flavour. Various "boutique" crops are available from New Zealand, France, Switzerland, England, the United States, and other countries—some of them organically grown. In the US, Pennsylvania Dutch saffron—known for its "earthy" notes—is produced in small quantities. Consumers may regard certain cultivars as "premium" quality. The "Aquila" saffron, or zafferano dell'Aquila, is defined by high safranal and crocin content, distinctive thread shape, unusually pungent aroma, and intense colour; it is grown exclusively on eight hectares in the Navelli Valley of Italy's Abruzzo region, near L'Aquila. It was first introduced to Italy by a Dominican friar from inquisition-era Spain. But the biggest saffron cultivation in Italy is in San Gavino Monreale, Sardinia, where it is grown on 40 hectares, representing 60% of Italian production; it too has unusually high crocin, picrocrocin, and safranal content. Another is the "Mongra" or "Lacha" saffron of Kashmir (Crocus sativus 'Cashmirianus'), which is among the most difficult for consumers to obtain.
β′ The β′ subunit is the largest subunit, and is encoded by the rpoC gene. The β′ subunit contains part of the active center responsible for RNA synthesis and contains some of the determinants for non-sequence-specific interactions with DNA and nascent RNA. It is split into two subunits in Cyanobacteria and chloroplasts. β The β subunit is the second-largest subunit, and is encoded by the rpoB gene. The β subunit contains the rest of the active center responsible for RNA synthesis and contains the rest of the determinants for non-sequence-specific interactions with DNA and nascent RNA. α (αI and αII) Two copies of the α subunit, being the third-largest subunit, are present in a molecule of RNAP: αI and αII (one and two). Each α subunit contains two domains: αNTD (N-terminal domain) and αCTD (C-terminal domain). αNTD contains determinants for assembly of RNAP. αCTD (C-terminal domain) contains determinants for interaction with promoter DNA, making non-sequence-non-specific interactions at most promoters and sequence-specific interactions at upstream-element-containing promoters, and contains determinants for interactions with regulatory factors. ω The ω subunit is the smallest subunit. The ω subunit facilitates assembly of RNAP and stabilizes assembled RNAP. In order to bind promoters, RNAP core associates with the transcription initiation factor sigma (σ) to form RNA polymerase holoenzyme. Sigma reduces the affinity of RNAP for nonspecific DNA while increasing specificity for promoters, allowing transcription to initiate at correct sites.
Sources: en.wikipedia.org
Generative AI models are used by chatbots such as ChatGPT, programming tools such as GitHub Copilot, text-to-image programs such as Midjourney, and text-to-video programs such as Runway Gen-2. Generative AI features have been added to existing commercially available services such as Microsoft Office (Microsoft Copilot), Google Photos, and the Adobe Suite (Adobe Firefly). Many generative AI models are also available as open-source software, including Stable Diffusion and the LLaMA language model. Smaller generative AI models with up to a few billion parameters can run on smartphones, embedded devices, and personal computers. For example, LLaMA-7B (a version with 7 billion parameters) can run on a Raspberry Pi 4 and one version of Stable Diffusion can run on an iPhone 11. Larger models with tens of billions of parameters can run on laptop or desktop computers. To achieve an acceptable speed, models of this size may require accelerators such as the GPU chips produced by NVIDIA and AMD or the Neural Engine included in Apple silicon products. For example, the 65 billion parameter version of LLaMA can be configured to run on a desktop PC. The advantages of running generative AI locally include protection of privacy and intellectual property, and avoidance of rate limiting and censorship. The subreddit r/LocalLLaMA in particular focuses on using consumer-grade gaming graphics cards through such techniques as compression.
=== Imaging === Imaging is not routinely indicated. It typically does not change plantar fasciitis management. When the diagnosis is not clinically apparent, lateral view X-rays of the ankle are the standard imaging modality to consider other causes, such as stress fractures or bone spur development. The plantar fascia has three fascicles; the central fascicle is the thickest at 4 mm, the lateral fascicle is 2 mm, and the medial less than one millimeter thick. In theory, plantar fasciitis becomes more likely with increased thickness at the calcaneal insertion. A thickness of more than 4.5 mm ultrasound and 4 mm on MRI are diagnostic. Other imaging findings, such as thickening of the plantar aponeurosis, are nonspecific and have limited diagnostic value. A Three-phase bone scan is a sensitive imaging modality. It can be used to monitor response to therapy, as demonstrated by decreased uptake after corticosteroid injections.
The fifth season of the American television drama series Scandal was ordered on May 7, 2015, by ABC, and began airing on September 24, 2015, in the United States on ABC. The season was produced by ABC Studios, in association with ShondaLand Production Company; the showrunner being Shonda Rhimes. The season continues the story of Olivia Pope's crisis management firm, Olivia Pope & Associates, and its staff, as well as staff at the White House in Washington, D.C. Season five has eleven series regulars, all returning from the previous season, out of which six are part of the original cast of eight regulars from the first season and three new regulars were added. The season will continue to air in the Thursday 9:00 pm timeslot, the same as the previous season as it was moved to make room for ShondaLand Production Company's new TV series, How to Get Away with Murder. On March 3, 2016, ABC announced that Scandal was renewed for a sixth season.
Sources: en.wikipedia.org
== Medical uses == Recombinant human parathyroid hormone (Natpara) is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in people with hypoparathyroidism. Recombinant human parathyroid hormone (Natpar) is indicated as adjunctive treatment of adults with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone. Recombinant human parathyroid hormone (Preotact) is indicated for the treatment of osteoporosis in postmenopausal women at high risk of fractures, but the marketing authorization has been withdrawn at the manufacturer's request.
. If there is just a single detector, then the analyzer can sweep across the mass spectrum one slit at a time. With multiple detectors, the speed of analysis increases. A pure magnetic sector analyzer can achieve resolution ~10,000. With an added electrostatic focusing field before or after the magnetic sector, the analyzer can achieve resolution ~100,000. Particularly unstable ions may disintegrate while passing through the analyzer. If it undergoes the reaction Mz+ → M'z+ + (other parts) when entering the analyzer, it would undergo a circular motion of radius
As Lebanese Christians formed the wealthy elite and the educated class, they have had a significant impact on the politics and culture of the Arab World, and they created a growing demand for Western-style education in law, medicine, science, engineering, and finance, and for the greater opportunities for wealth.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.